Dengue Vaccine Appears Protective Against Asymptomatic Infection

Further analysis of two clinical trials of the tetravalent CYD-TDV dengue vaccine finds evidence of efficacy against asymptomatic as well as symptomatic infections.

The mosquito-borne dengue virus causes significant morbidity and mortality in tropical regions worldwide. Two recent clinical trials found that a live, recombinant, attenuated, three-dose tetravalent vaccine was protective against dengue fever in studies performed both in Asia and Latin America (NEJM JW Infect Dis Sep 2014 and Lancet 2014; 384:1358 and 1327; NEJM JW Infect Dis Dec 2014 and N Engl J Med 2015; 372:113). Because individuals with asymptomatic infection could serve as an important reservoir for the dengue virus, researchers now report on a manufacturer-supported assessment of the vaccine's efficacy against asymptomatic dengue infection, using data from the two clinical trials.

Among 3736 study participants (2510 and 1226 in the v…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Dengue Vaccine Appears Protective Against Asymptomatic Infection

Topics

Reviewing Author